CROs/Service Providers

George Clinical acquires Vector Oncology’s Pharma Services

Thursday, May 4, 2017

George Clinical, a full-service CRO in the Asia-Pacific region, and Vector Oncology, a Memphis-based leader in oncology research and data analytics, announced that George Clinical has acquired Vector Oncology’s Pharma Services (CRO) Division. Effective immediately, the transaction has the dual purpose of strengthening the ability of George Clinical to provide scientifically led oncology trial delivery solutions throughout the Asia-Pacific, and, more broadly, to expand George Clinical’s  operational expertise and scientific leadership in vascular, renal and respiratory diseases, neurology and endocrinology throughout the U.S.

[Read More]

Metrion Biosciences, Venomtech partner

Monday, April 24, 2017

Metrion Biosciences, a specialist ion channel CRO and drug discovery company, and Venomtech, a U.K. biotechnology company with a venom library, announced a collaboration agreement that will see the two companies combine their resources and expertise to search for novel ion channel modulators for use in drug discovery research.

[Read More]

Greater Gift Initiative partners with INC Research

Friday, April 14, 2017

The Greater Gift Initiative (GGI), a Winston-Salem, NC 501(c)3 nonprofit, partnered with INC Research, a global phase I to IV CRO with experience in vaccine clinical research. GGI’s mission is to advance global health and highlight the greater good of clinical trial participation by gifting a vaccine to a child in need in honor of each clinical trial volunteer. The vision of GGI is to serve as a philanthropic connector among clinical trial sites, individual investigators, CROs and sponsors by conveying a unified message to the clinical volunteer community that their participation does matter.

[Read More]

Median Technologies, inVentiv Health partner on medical image analysis

Wednesday, April 12, 2017

Median Technologies, an Imaging Phenomics Company, and inVentiv Health, a biopharmaceutical professional services company, have announced a strategic alliance to offer biopharmaceutical clients with best-in-class medical image analysis and management services for early- to late-stage oncology clinical trials. The alliance will provide inVentiv clients with the most advanced imaging biomarkers, at a time when 73% of cancer compounds in clinical trials involve biomarkers in their research and development design.

[Read More]